Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""sorafenib"" wg kryterium: Temat


Tytuł:
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
Autorzy:
Peng TR; Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Wu CC; Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Medicine, Tzu Chi University, Hualien, Taiwan.
Chang SY; Division of Hematology & Oncology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Taipei, Taiwan.
Chen YC; Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Wu TW; Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
Hsu CS; Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan; Liver Disease Prevention and Treatment Center, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan; School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2022 Nov; Vol. 112, pp. 109223. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Nivolumab*/therapeutic use
Sorafenib*/therapeutic use
Humans ; alpha-Fetoproteins/analysis ; Immune Checkpoint Inhibitors ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use
Czasopismo naukowe
Tytuł:
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Autorzy:
de la Cruz-Ojeda P; Institute of Biomedicine of Seville (IBiS), Hospital University 'Virgen del Rocío'/CSIC/University of Seville, 41013 Seville, Spain.; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; Department of Medical Physiology and Biophysics, University of Seville, 41004 Seville, Spain.
Schmid T; Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60528 Frankfurt, Germany.
Boix L; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain.
Moreno M; Department of General Surgery, Hospital University 'Virgen del Rocío'/CSIC/University of Seville/IBIS, 41013 Seville, Spain.
Sapena V; BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain.
Praena-Fernández JM; Department of Statistics and Operations Research, University of Granada, 18011 Granada, Spain.
Castell FJ; Department of Radiology, Hospital University 'Virgen del Rocío'/CSIC/University of Seville/IBIS, 41013 Seville, Spain.
Falcón-Pérez JM; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; Exosomes Lab, CIC bioGUNE, 48160 Derio, Spain.
Reig M; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain.
Brüne B; Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60528 Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt, 60528 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe-University Frankfurt, 60528 Frankfurt, Germany.; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 60528 Frankfurt, Germany.
Gómez-Bravo MA; Department of General Surgery, Hospital University 'Virgen del Rocío'/CSIC/University of Seville/IBIS, 41013 Seville, Spain.
Giráldez Á; Unit for the Clinical Management of Digestive Diseases, Hospital University 'Virgen del Rocío'/CSIC/University of Seville/IBIS, 41013 Seville, Spain.
Bruix J; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, 08036 Barcelona, Spain.
Ferrer MT; Unit for the Clinical Management of Digestive Diseases, Hospital University 'Virgen del Rocío'/CSIC/University of Seville/IBIS, 41013 Seville, Spain.
Muntané J; Institute of Biomedicine of Seville (IBiS), Hospital University 'Virgen del Rocío'/CSIC/University of Seville, 41013 Seville, Spain.; Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), 28029 Madrid, Spain.; Department of Medical Physiology and Biophysics, University of Seville, 41004 Seville, Spain.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Aug 28; Vol. 11 (17). Date of Electronic Publication: 2022 Aug 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
Sorafenib*/pharmacology
Sorafenib*/therapeutic use
Biomarkers ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/genetics ; Liver Neoplasms/metabolism
Czasopismo naukowe
Tytuł:
Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Autorzy:
Nour MA; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Kheradmand F; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. .
Rasmi Y; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.; Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.
Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. .; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. .; Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, 516615731, Iran. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2022 Aug 16; Vol. 39 (11), pp. 165. Date of Electronic Publication: 2022 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Sorafenib*/pharmacology
Sorafenib*/therapeutic use
Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; RNA, Small Interfering/genetics ; alpha7 Nicotinic Acetylcholine Receptor/genetics ; alpha7 Nicotinic Acetylcholine Receptor/metabolism ; alpha7 Nicotinic Acetylcholine Receptor/therapeutic use
Czasopismo naukowe
Tytuł:
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats.
Autorzy:
Cui Y; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.
Li Y; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.; Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050017, China.
Guo C; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.; Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050017, China.
Li Y; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.; Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050017, China.
Ma Y; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.; Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050017, China.
Dong Z; National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Aug 24; Vol. 27 (17). Date of Electronic Publication: 2022 Aug 24.
Typ publikacji:
Journal Article
MeSH Terms:
Canagliflozin*/pharmacokinetics
Phenylurea Compounds*/pharmacokinetics
Quinolines*/pharmacokinetics
Sorafenib*/pharmacokinetics
Animals ; Carcinoma, Hepatocellular/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Drug Interactions ; Liver Neoplasms/drug therapy ; Protein Kinase Inhibitors/pharmacokinetics ; Rats ; Sodium-Glucose Transporter 2 Inhibitors/pharmacokinetics
Czasopismo naukowe
Tytuł:
Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy.
Autorzy:
Sun Y; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Guan X; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Zhang T; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Li Y; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Shi H; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Chitakunye AT; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Hong H; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Zhang S; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Zhu Q; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China.
Cai L; Department of Biopharmaceuticals, School of Pharmaceutics Sciences, Wenzhou Medical University, Chashan, Wenzhou, 325035, Zhejiang Province, China. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2022 Aug 16; Vol. 39 (11), pp. 159. Date of Electronic Publication: 2022 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Membrane Proteins*/genetics
Membrane Proteins*/metabolism
Sorafenib*/pharmacology
Animals ; Apoptosis ; Autophagy ; Cell Line, Tumor ; Cell Proliferation ; Drug Resistance, Neoplasm ; Humans ; Mice ; Mice, Nude ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis.
Autorzy:
Jiang H; Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, China; Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, China.
Wang C; Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, China; Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, Shandong 250014, China.
Zhang A; Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, China.
Li Y; Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, China.
Li J; Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, China.
Li Z; Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, Shandong 250014, China.
Yang X; Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, China.
Hou Y; Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, China; Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, Shandong 250014, China. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Sep; Vol. 153, pp. 113280. Date of Electronic Publication: 2022 Jun 17.
Typ publikacji:
Journal Article
MeSH Terms:
Activating Transcription Factor 4*/metabolism
Cardiotoxicity*
Ferroptosis*
Sorafenib*/adverse effects
Animals ; Liver Neoplasms/metabolism ; Mice
Czasopismo naukowe
Tytuł:
Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Autorzy:
Lai X; Department of Integrated Chinese and Western Medicine Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Wang A; Department of Integrated Chinese and Western Medicine Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Pokaż więcej
Źródło:
Computational intelligence and neuroscience [Comput Intell Neurosci] 2022 Aug 23; Vol. 2022, pp. 6336107. Date of Electronic Publication: 2022 Aug 23 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Chemoembolization, Therapeutic*
Drugs, Chinese Herbal*/therapeutic use
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Sorafenib*/therapeutic use
Carcinoembryonic Antigen ; Case-Control Studies ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Quality of Life ; Retrospective Studies ; alpha-Fetoproteins
Czasopismo naukowe
Tytuł:
Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
Autorzy:
Wei T; Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China; School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lin R; School of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Fu X; School of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Lu Y; School of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen 518055, Guangdong, China.
Zhang W; Shenzhen University General Hospital, Shenzhen University, Shenzhen 518061, Guangdong, China.
Li Z; Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Zhang J; School of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China; Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen 518055, Guangdong, China. Electronic address: .
Wang H; Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China; Shenzhen University General Hospital, Shenzhen University, Shenzhen 518061, Guangdong, China. Electronic address: .
Pokaż więcej
Źródło:
Pharmacological research [Pharmacol Res] 2022 Jun; Vol. 180, pp. 106244. Date of Electronic Publication: 2022 May 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacology
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Sorafenib*/pharmacology
Antigens, Neoplasm ; Carbonic Anhydrase IX/genetics ; Carbonic Anhydrase IX/metabolism ; Cell Line, Tumor ; Cell Proliferation ; DNA (Cytosine-5-)-Methyltransferase 1/genetics ; DNA (Cytosine-5-)-Methyltransferase 1/metabolism ; Drug Resistance, Neoplasm ; Epigenesis, Genetic ; Humans ; Kruppel-Like Factor 4/genetics ; Kruppel-Like Factor 4/metabolism ; Metallothionein/genetics ; Metallothionein/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł:
A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.
Autorzy:
Abuhelwa AY; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Badaoui S; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Yuen HY; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
McKinnon RA; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Ruanglertboon W; Department of Pharmacology, Division of Health and Applied Sceinces, Prince of Songkla University, Songkhla, Thailand.
Shankaran K; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Tuteja A; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia.
Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, SA, 5042, Australia. .
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Apr; Vol. 89 (4), pp. 479-485. Date of Electronic Publication: 2022 Feb 28.
Typ publikacji:
Clinical Trial, Phase III; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Hand-Foot Syndrome*/etiology
Liver Neoplasms*/drug therapy
Sorafenib*/adverse effects
Female ; Humans ; Machine Learning ; Male ; Risk Assessment/methods
Czasopismo naukowe
Tytuł:
Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Autorzy:
Byun JK; Research Institute of Aging and Metabolism, Kyungpook National University, Daegu, Korea.; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Lee S; Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea.; BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University, Daegu, Korea.
Kang GW; Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea.
Lee YR; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Park SY; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Song IS; Research Institute of Pharmaceutical Science, College of Pharmacy, Kyungpook National University, Daegu, Korea.
Yun JW; Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Korea.
Lee J; Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi YK; Research Institute of Aging and Metabolism, Kyungpook National University, Daegu, Korea. .; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea. .
Park KG; Research Institute of Aging and Metabolism, Kyungpook National University, Daegu, Korea. .; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea. .; Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Mar 14; Vol. 41 (1), pp. 98. Date of Electronic Publication: 2022 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular/*complications
Carcinoma, Hepatocellular/*drug therapy
Cysteine/*therapeutic use
Ferroptosis/*drug effects
Liver Neoplasms/*complications
Liver Neoplasms/*drug therapy
Pinocytosis/*drug effects
Protein Kinase Inhibitors/*therapeutic use
Sorafenib/*therapeutic use
Animals ; Carcinoma, Hepatocellular/pathology ; Cysteine/pharmacology ; Female ; Humans ; Liver Neoplasms/pathology ; Male ; Mice ; Protein Kinase Inhibitors/pharmacology ; Sorafenib/pharmacology
Czasopismo naukowe
Tytuł:
Identification of Sorafenib as a Treatment for Type 1 Diabetes.
Autorzy:
Zeng Q; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Song J; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Wang D; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Sun X; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiao Y; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhang H; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiao Y; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhou Z; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Deng T; National Clinical Research Center for Metabolic Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China.; Key Laboratory of Diabetes Immunology, Ministry of Education, and Metabolic Syndrome Research Center, The Second Xiangya Hospital of Central South University, Changsha, China.; Clinical Immunology Center, The Second Xiangya Hospital of Central South University, Changsha, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Feb 15; Vol. 13, pp. 740805. Date of Electronic Publication: 2022 Feb 15 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 1*/drug therapy
Sorafenib*/pharmacology
Sorafenib*/therapeutic use
Animals ; Interleukin-12 ; Mice ; Mice, Inbred NOD ; Th1 Cells
Czasopismo naukowe
Tytuł:
Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
Autorzy:
Kong H; The First Ward of Hepatology Department, Fifth Medical Center of Chinese Pla General Hospital, Beijing, China.
Sun J; Internal Medicine- Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zhang W; The First Ward of Hepatology Department, Fifth Medical Center of Chinese Pla General Hospital, Beijing, China.
Zhang H; The First Ward of Hepatology Department, Fifth Medical Center of Chinese Pla General Hospital, Beijing, China.
Li H; Department of Infectious Diseases, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China.
Pokaż więcej
Źródło:
Bioengineered [Bioengineered] 2022 Feb; Vol. 13 (2), pp. 3108-3121.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Drug Resistance, Neoplasm/*genetics
Methyltransferases/*genetics
RNA, Long Noncoding/*physiology
Sorafenib/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Animals ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Cell Survival/drug effects ; Cell Survival/genetics ; Female ; Gene Expression Regulation, Enzymologic ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice ; Mice, Nude ; Middle Aged ; Sorafenib/pharmacology ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł:
Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Autorzy:
Lu Y; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.
Chan YT; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.
Tan HY; Centre for Chinese Herbal Medicine Drug Development, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Zhang C; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.
Guo W; Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, People's Republic of China.
Xu Y; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China.
Sharma R; Proteomics and Metabolomics Core Facility, The University of Hong Kong, Hong Kong, China.
Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, USA.
Zheng YC; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.
Wang N; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China. .
Feng Y; School of Chinese Medicine, The University of Hong Kong, Hong Kong, China. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Jan 03; Vol. 41 (1), pp. 3. Date of Electronic Publication: 2022 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Carcinoma, Hepatocellular/*drug therapy
Coenzyme A Ligases/*metabolism
Epigenesis, Genetic/*genetics
Ferroptosis/*genetics
Liver Neoplasms/*drug therapy
Sorafenib/*therapeutic use
Animals ; Antineoplastic Agents/pharmacology ; Carcinoma, Hepatocellular/pathology ; Drug Resistance, Neoplasm ; Humans ; Liver Neoplasms/pathology ; Mice, Inbred NOD ; Sorafenib/pharmacology
Czasopismo naukowe
Tytuł:
Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway.
Autorzy:
Yuan S; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Wei C; Department of Urology, The Second People's Hospital of Hefei, Hefei, China.
Liu G; School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
Zhang L; School of Pharmacy, Anhui Medical University, Hefei, China.
Li J; School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
Li L; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cai S; School of Pharmacy, Anhui Medical University, Hefei, China.
Fang L; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Pokaż więcej
Źródło:
Cell proliferation [Cell Prolif] 2022 Jan; Vol. 55 (1), pp. e13158. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Ferroptosis*/drug effects
Signal Transduction*/drug effects
Amino Acid Transport System y+/*metabolism
Hepatic Stellate Cells/*pathology
Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
Liver Cirrhosis/*drug therapy
Sorafenib/*therapeutic use
Actins/metabolism ; Animals ; Cell Line ; Collagen Type I/metabolism ; Hepatic Stellate Cells/drug effects ; Hepatic Stellate Cells/metabolism ; Hepatocytes/drug effects ; Hepatocytes/metabolism ; Hepatocytes/pathology ; Liver Cirrhosis/pathology ; Macrophages/drug effects ; Macrophages/metabolism ; Macrophages/pathology ; Male ; Mice, Inbred C57BL ; Models, Biological ; Protein Stability/drug effects ; Sorafenib/pharmacology
Czasopismo naukowe
Tytuł:
Sorafenib induces pigmentation via the regulation of β-catenin signalling pathway in melanoma cells.
Autorzy:
Kim KI; Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea.; Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Korea.; Department of Dermatology and Institute of Health Sciences, School of Medicine, Gyeongsang National University & Hospital, Jinju, Korea.
Jung KE; Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea.
Shin YB; Department of Dermatology and Institute of Health Sciences, School of Medicine, Gyeongsang National University & Hospital, Jinju, Korea.
Kim CD; Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea.; Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Korea.
Yoon TJ; Department of Dermatology and Institute of Health Sciences, School of Medicine, Gyeongsang National University & Hospital, Jinju, Korea.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2022 Jan; Vol. 31 (1), pp. 57-63. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Melanoma/*pathology
Pigmentation/*drug effects
Skin Neoplasms/*pathology
Sorafenib/*pharmacology
beta Catenin/*metabolism
Antineoplastic Agents/metabolism ; Cell Line, Tumor ; Humans ; Signal Transduction/drug effects ; Sorafenib/metabolism
Czasopismo naukowe
Tytuł:
DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Autorzy:
Gan H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Li L; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Hu X; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Cai J; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Hu X; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Zhang H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Zhao N; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Xu X; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Guo H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Pang P; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Cell Line, Tumor ; Apoptosis ; Cell Proliferation ; DEAD-box RNA Helicases/genetics ; DEAD-box RNA Helicases/pharmacology
Czasopismo naukowe
Tytuł:
Sorafenib decreases glycemia by impairing hepatic glucose metabolism.
Autorzy:
Ma J; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Sui F; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Liu Y; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Yuan M; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Dang H; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Liu R; Department of Radio-Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Shi B; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China.
Hou P; Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China. .; Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xi'an, P.R. China. .
Pokaż więcej
Źródło:
Endocrine [Endocrine] 2022 Dec; Vol. 78 (3), pp. 446-457. Date of Electronic Publication: 2022 Oct 07.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*
Diabetes Mellitus, Experimental*/metabolism
Insulins*/metabolism
Insulins*/pharmacology
Insulins*/therapeutic use
Mice ; Animals ; Blood Glucose/metabolism ; Glucose/metabolism ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Proto-Oncogene Proteins c-myc/metabolism ; Proto-Oncogene Proteins c-myc/pharmacology ; Proto-Oncogene Proteins c-myc/therapeutic use ; Signal Transduction ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Liver/metabolism ; Insulin/metabolism
Czasopismo naukowe
Tytuł:
Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches.
Autorzy:
Abdu S; Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia.
Juaid N; Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia.
Amin A; Biology Department, UAE University, Al Ain 15551, United Arab Emirates.
Moulay M; Embryonic Stem Cell Research Unit, King Fahd Medical Research Center, King Abdul Aziz University, Jeddah 22252, Saudi Arabia.
Miled N; Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia.; Functional Genomics and Plant Physiology Research Unit, Higher Institute of Biotechnology Sfax, University of Sfax, BP261 Road Soukra Km4, Sfax 3038, Tunisia.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Nov 21; Vol. 27 (22). Date of Electronic Publication: 2022 Nov 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/metabolism
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Quercetin/pharmacology ; Quercetin/therapeutic use ; Xenograft Model Antitumor Assays ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Autorzy:
Suk FM; Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Wu CY; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chiu WC; School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.; Research Center of Geriatric Nutrition, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.; Department of Nutrition, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chien CY; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.; Department of Laboratory Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan.
Chen TL; Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Liao YJ; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Nov 18; Vol. 27 (22). Date of Electronic Publication: 2022 Nov 18.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Male ; Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Hydroxymethylglutaryl-CoA Synthase/genetics ; Hydroxymethylglutaryl-CoA Synthase/metabolism ; Ketones/therapeutic use ; Ketone Bodies/metabolism ; Ketone Bodies/therapeutic use ; Extracellular Signal-Regulated MAP Kinases ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment.
Autorzy:
Koch M; Physical Biology, Buchmann Institute for Molecular Life Sciences (BMLS), Goethe University Frankfurt, 60438 Frankfurt am Main, Germany.
Nickel S; Department of Visceral, Transplant, Thoracic and Vascular Surgery, University of Leipzig Medical Center, 04103 Leipzig, Germany.; Division of General, Visceral and Vascular Surgery, University Hospital Jena, 07740 Jena, Germany.
Lieshout R; Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands.
Lissek SM; Experimental Medicine and Therapy Research, University of Regensburg, 93053 Regensburg, Germany.
Leskova M; Physical Biology, Buchmann Institute for Molecular Life Sciences (BMLS), Goethe University Frankfurt, 60438 Frankfurt am Main, Germany.
van der Laan LJW; Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands.
Verstegen MMA; Department of Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, 3015 CN Rotterdam, The Netherlands.
Christ B; Department of Visceral, Transplant, Thoracic and Vascular Surgery, University of Leipzig Medical Center, 04103 Leipzig, Germany.
Pampaloni F; Physical Biology, Buchmann Institute for Molecular Life Sciences (BMLS), Goethe University Frankfurt, 60438 Frankfurt am Main, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Nov 15; Vol. 11 (22). Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Cholangiocarcinoma*/diagnostic imaging
Cholangiocarcinoma*/drug therapy
Cholangiocarcinoma*/pathology
Bile Duct Neoplasms*/diagnostic imaging
Bile Duct Neoplasms*/drug therapy
Bile Duct Neoplasms*/pathology
Humans ; Organoids/pathology ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Ki-67 Antigen ; Bile Ducts, Intrahepatic/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz